Corporate | 1 August 2011 10:30


STADA: STADA sales companies achieve very good results in fourth DAK tender in the German generics market


STADA Arzneimittel AG / Key word(s): Miscellaneous

01.08.2011 / 10:30


Corporate News

STADA sales companies achieve very good results in fourth
DAK tender in the German generics market

Bad Vilbel, August 1, 2011 – The STADA sales companies STADApharm GmbH and ALIUD PHARMA GmbH achieved, in the view of the STADA Executive Board, very good results in the fourth round of tenders of the Deutsche Angestellte Krankenkasse (DAK) (German insurance organization for salaried employees) for discount agreements pursuant to Section 130 a SGB V valid throughout Germany.

The DAK, which insures approx. 6.5 million of the total of approx. 70 million publicly insured persons in Germany, thus concluded respective contracts with these two STADA sales companies, each for ten active ingredients from a total of 33 active ingredients – including some product launches and in-house production.

The contracts are legally effective, start on October 1, 2011 and have a regular term of two years.

In the case of the discount agreements organized on a multi-source basis, the respective STADA sales company is one of three contractual partners of the DAK.

In view of these newly concluded discount agreements with the DAK and the large-volume awards previously received from the AOK, STADA’s Executive Board expects that the Group’s market share by volume in the German market will increase further. Overall, STADA now has discount agreements with almost all public health insurance organizations in the German market.

Additional information:
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2-18 / D – 61118 Bad Vilbel /
Tel.: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / E-mail: communications@stada.de
Or visit us on the Internet at www.stada.com .



End of Corporate News


01.08.2011 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard); Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart
End of News DGAP News-Service

133850  01.08.2011